U.S. Biotech Stock News

Lamar Advertising (LAMR) just handed the keys to its core Outdoor Division to Ross Reilly, effective January 1, 2026, a leadership move that directly ties strategy, acquisitions and digital growth together. See our latest analysis for Lamar Advertising. That leadership shuffle lands as Lamar’s $127.31 share price has quietly trended higher, with a solid year to date share price return and standout multi year total shareholder returns suggesting sentiment is leaning toward steady, dividend...

How Merck's Recent Performance Frames the Valuation Story With Merck’s share price hovering just above the 100 dollar mark, many investors are wondering whether they are looking at a solid long term compounder or a stock that has already priced in most of its upside. The recent performance numbers offer a useful starting point for framing that valuation debate. Over the last week, Merck has inched up around 0.8%, adding to a stronger 6.4% gain over the past month and a more modest 1.9% return...

Essential Properties Realty Trust (EPRT) has been quietly grinding higher over the past three years, and its latest trading session keeps that slow, steady story intact despite a flat near term performance. See our latest analysis for Essential Properties Realty Trust. That modest pullback in the share price over the past month sits against a far more upbeat backdrop, with a resilient 1 year total shareholder return and a standout 3 year total shareholder return suggesting momentum is still...

HEICO (HEI) just wrapped up FY 2025 with fourth quarter revenue of about $1.2 billion and basic EPS of $1.35, capping a trailing twelve month run that saw revenue reach roughly $4.5 billion and EPS hit $4.97 alongside a net income of $690 million. Over the last year, the company has seen revenue climb from about $3.9 billion to $4.5 billion, while basic EPS stepped up from $3.71 to $4.97 in the trailing figures, signaling a business that is translating top line expansion into healthier...

Visa (V) just checked off two big boxes on the future of payments timeline, moving AI shopping agents into real world use and turning USDC settlement for U.S. partners from pilot to product. See our latest analysis for Visa. Investors seem to be warming to that story, with Visa’s 1 month share price return of 7.75 percent helping build momentum on top of an 11.08 percent year to date share price gain and a robust 3 year total shareholder return of 73.56 percent. If Visa’s AI and stablecoin...

Etsy (ETSY) shares climbed after the board approved a fresh 750 million dollar buyback, lifting total potential repurchases to nearly 1 billion dollars and announcing a revamped leadership lineup. See our latest analysis for Etsy. The new buyback plan and leadership refresh land at a delicate moment, with Etsy’s roughly 2 percent year to date share price return contrasting sharply with a five year total shareholder return of about negative 71 percent. This suggests today’s pop could be early...

Rivian recently used its first Autonomy & AI Day to unveil an in-house 5nm autonomy chip, a next-generation ACM3 compute module with LiDAR for upcoming R2 models, and an Autonomy+ subscription service, while also announcing a future hands-free driving feature for current R1 vehicles. At the same time, former Patagonia CEO Rose Marcario’s decision to leave Rivian’s board while remaining chair of the Rivian Foundation underscores how the company is coupling an advanced autonomy roadmap with an...

National Health Investors (NHI) has quietly rewarded patient shareholders, with the stock up about 17% over the past year while maintaining steady revenue and earnings growth. This makes it an interesting income-focused REIT to revisit. See our latest analysis for National Health Investors. That steady climb in sentiment is visible in the numbers, with the latest share price at $77.84, a positive year to date share price return, and a strong one year and multi year total shareholder return...

Gilead Sciences (GILD) just strung together a trio of catalysts that the market could not ignore, including fresh HIV wins and a high profile U.S. drug pricing deal that reframes its long term growth story. See our latest analysis for Gilead Sciences. The latest HIV data and U.S. pricing accord appear to be feeding into a stronger narrative for Gilead, with the stock’s share price up meaningfully year to date and longer term total shareholder returns reinforcing that momentum. If...

PACS Group, Inc. recently named Kelly Priegnitz as Chief Compliance Officer and Trent Bingham as Chief Human Resources Officer, bolstering its leadership in compliance and workforce management after a series of acquisitions and a credit agreement amendment earlier in 2025. The addition of seasoned executives with deep healthcare compliance and human capital experience underscores PACS Group’s focus on governance, culture, and operational discipline as it grows its skilled nursing...

If you are wondering whether Synopsys is still worth buying at these levels or if the best gains are already in the rearview mirror, this article will walk you through what the current price really implies. The stock has bounced about 2.4% over the last week and roughly 20.0% over the past month, even though it is still down around 3.9% year to date and about 5.8% over the last year. Longer term holders remain well ahead with 44.8% and 80.9% returns over 3 and 5 years. Behind those swings,...

In recent months, United Parcel Service has moved ahead with a broad overhaul of its business, cutting tens of thousands of jobs, consolidating facilities, investing in automation, and expanding into higher-margin areas like healthcare logistics while also rolling out AI tools to curb fraudulent retail returns. Early signs such as rising revenue per package, a long-running commitment to its dividend, and a pivot away from lower-margin e-commerce work suggest UPS is reshaping its core...

If you are wondering whether Norfolk Southern at around $291 a share is still worth climbing aboard or if the train has already left the station, this piece is for you. The stock is up 24.2% year to date and 27.1% over the last year, even after a recent 1.9% dip this week and a 3.4% gain over the past month. This hints that the market is still actively reassessing its long term prospects. Recent headlines have focused on Norfolk Southern’s ongoing safety and network efficiency initiatives,...

Earlier this month, Harmony Biosciences announced initial open-label extension data from its Phase 3 ARGUS trial of EPX-100 in Dravet syndrome, showing clinically meaningful seizure reductions and a generally favorable safety profile over long-term treatment. Beyond the seizure data, the twice-daily liquid EPX-100, derived from a proprietary zebrafish screening platform targeting 5HT-2 serotonin receptors, highlights Harmony’s push into rare, treatment-resistant epilepsies such as Dravet and...

If you are wondering whether EVERTEC at around $29 a share is a value opportunity or a value trap, you are not alone. That is exactly what we are going to unpack here. Despite a modest 0.6% gain over the last month, the stock is still down 15.8% year to date and 13.1% over the past year, which suggests sentiment has cooled even as the underlying business keeps grinding on. Recent headlines around digital payments infrastructure in Latin America and the Caribbean, along with ongoing shifts...

BigBear.ai Holdings (BBAI) is back on traders radar after unveiling a new partnership with C Speed that plugs its ConductorOS AI engine into C Speed radar systems for real time defense threat detection. See our latest analysis for BigBear.ai Holdings. That C Speed deal lands after a choppy stretch where dilution worries and the Ask Sage acquisition weighed on sentiment, yet BigBear.ai still sports a punchy year to date share price return and a triple digit one year total shareholder return...

Wondering if Netflix is still worth buying after its big run over the last few years, or if the easy money has already been made? You are not alone. That is exactly what this breakdown is here to unpack. Despite a powerful 220.0% gain over 3 years and 83.6% over 5 years, the stock has cooled recently, with a 6.4% year to date rise, 3.8% over the last year, but a softer -14.2% in the last month and -0.8% over the last week. This hints at shifting sentiment and a more nuanced risk reward...

Earlier this month, iRadimed Corporation’s board approved a special cash dividend of US$0.50 per share, payable on December 30, 2025, to shareholders of record as of December 17, 2025. This one-off payout highlights the company’s capacity to return excess cash to investors while its MRI-compatible devices continue to support recurring revenue streams. We’ll now examine how this special cash dividend, as a signal of balance-sheet strength, shapes IRADIMED’s existing investment...

DigitalOcean Holdings (DOCN) caught fresh attention after its shares climbed about 4% following the launch of its Gradient AI Agent Development Kit, which came on the heels of a multi year AI partnership with Persistent Systems. See our latest analysis for DigitalOcean Holdings. Beyond today’s pop, DigitalOcean’s 30 day share price return of 7.78% and 90 day share price return of 29.94% suggest momentum is building. A 3 year total shareholder return of 92% points to a compelling longer term...

If you are wondering whether UnitedHealth Group is now quietly trading at a discount after a rough stretch, or if that low price is a value trap in disguise, this breakdown is for you. After a choppy year, the stock is down about 35.1% year to date and 32.9% over the last 12 months, even though it has managed a 5.9% gain over the past month despite a 4.2% dip in the last week. Much of this volatility has been driven by headlines around rising medical cost trends, regulatory scrutiny in key...

TE Connectivity (TEL) has quietly delivered a strong run over the past year, and with shares hovering near 229 dollars, investors are starting to revisit whether the current price still reflects future growth potential. See our latest analysis for TE Connectivity. That steady climb in the share price to about 229.98 dollars, backed by a robust year to date share price return and a strong multi year total shareholder return, suggests momentum is still building as investors reassess TE...

In December 2025, Exxon Mobil updated its 2030 corporate plan, lifting expected earnings and cash flow by US$5.00 billion without raising capital spending, while also securing new North Sea offtake and financing agreements and facing operational changes such as the planned closure of its Fife Ethylene Plant in the UK. The company’s ability to project higher long-term profitability on the same capital budget, alongside disciplined shareholder returns and portfolio reshaping, highlights how...

If you are wondering whether Eli Lilly is still worth buying after its massive run up, or if the market has already priced in all the good news, you are not alone. The stock has climbed 4.3% over the last week, 37.7% year to date, and an enormous 577.5% over five years. This naturally raises questions about how much upside is really left from here. Recent gains have been driven largely by excitement around Eli Lilly's leadership in obesity and diabetes treatments, with blockbuster demand for...

Dominion Energy (D) has been getting fresh attention after its nuclear focused Memorandum of Understanding with Amazon and its inclusion among top utility picks for hedge funds, all against a backdrop of surging data center driven demand. See our latest analysis for Dominion Energy. Even with the Amazon nuclear partnership and hedge fund interest grabbing headlines, Dominion’s share price return has been steadier than explosive, with a roughly 9 percent year to date gain and a one year total...